Counterpoint: Is there a need for supplemental XRT in intermediate-risk prostate cancer patients?

摘要

Permanent brachytherapy has become an accepted modality for treating localized prostate cancer. Low-risk disease can be managed with seed implant monotherapy and high-risk disease with a combination of seeds and external beam radiotherapy (EBRT) with or without hormone therapy (HT). Treatment of the intermediate-risk group (IRG) remains controversial. Is monotherapy or combination treatment the best option? To make the case for monotherapy adequate radiation dose needs to be delivered. In addition to cancer control, differences between monotherapy and combination therapy in morbidity, secondary cancer (SC) risk, and costs also need to be addressed.